Amgen Inc. $AMGN Shares Sold by Danske Bank A S

Danske Bank A S decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 18.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 291,974 shares of the medical research company’s stock after selling 66,197 shares during the quarter. Danske Bank A S’s holdings in Amgen were worth $95,566,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AMGN. Board of the Pension Protection Fund purchased a new position in shares of Amgen in the 4th quarter worth $26,000. Olistico Wealth LLC purchased a new position in shares of Amgen in the 4th quarter worth $33,000. Ares Financial Consulting LLC purchased a new position in shares of Amgen in the 4th quarter worth $34,000. Holos Integrated Wealth LLC purchased a new position in shares of Amgen in the 4th quarter worth $37,000. Finally, Cloud Capital Management LLC purchased a new position in shares of Amgen in the 3rd quarter worth $34,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on AMGN. Freedom Capital lowered Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. TD Cowen reaffirmed a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Morgan Stanley increased their target price on Amgen from $309.00 to $326.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Wells Fargo & Company increased their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 19th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $356.62.

Amgen Stock Up 2.4%

Shares of NASDAQ:AMGN opened at $346.25 on Friday. The company has a market capitalization of $186.86 billion, a price-to-earnings ratio of 24.33, a price-to-earnings-growth ratio of 3.34 and a beta of 0.47. The company has a 50 day moving average of $358.07 and a two-hundred day moving average of $340.45. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.73 by $0.42. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts forecast that Amgen Inc. will post 22.16 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is 70.84%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results: Amgen reported EPS of $5.15 vs. consensus ~$4.74 and revenue of $8.62B vs. ~$8.58B — beats on both lines and sales rose ~4%, supporting the near?term earnings story. Amgen’s (NASDAQ:AMGN) Q1 CY2026 sales top estimates
• Positive Sentiment: Mgmt commentary/slides: Management framed 2026 as a “springboard” year and highlighted six growth drivers; investors may take this as confidence in product mix and pipeline execution. Amgen (AMGN) Q1 2026 Earnings Transcript
• Positive Sentiment: Pipeline progress: Amgen is advancing a broader development program for weight?loss candidate MariTide and submitted a label update to the FDA for an autoimmune drug — signs of R&D activity that could drive medium?term growth. Amgen sales rise 4% in first quarter, submits label update to FDA on autoimmune drug
• Neutral Sentiment: Guidance: FY?2026 EPS guidance set to 21.700–23.100 (consensus ~22.29); revenue guidance $37.1B–$38.5B (consensus ~37.8B) — range leaves room for beats or misses, which could sustain volatility as analysts model the year. Amgen Q1 press release and slide deck
• Neutral Sentiment: Analyst sentiment: Wall Street remains moderately optimistic on targets but Amgen has underperformed the market over the past year — analysts will reassess models after the quarter. What Are Wall Street Analysts’ Target Price for Amgen Stock?
• Negative Sentiment: Tavneos regulatory risk: An FDA advisory panel raised efficacy/data concerns for Tavneos and there have been reports of a proposed U.S. withdrawal — this is a material downside catalyst for a rare?disease franchise and could pressure sentiment until resolved. Amgen faces U.S. withdrawal of rare disorder therapy Tavneos

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.